Another mechanistic study found that the inhibition of reactive oxygen species (ROS), the activation of the STAT3/Akt/Bcl-2 pathway, and the induced metastatic capacity of HCC cells were the leading causes of enhanced drug resistance in HCC (Wang et al., 2018). This evidence concerns the gene BCL2 and hepatocellular carcinoma.